Press Release

FOR IMMEDIATE RELEASE
June 13, 2006

Supernus Pharmaceuticals Announces Partnership with United Therapeutics

Rockville, MD - June 13, 2006 - Supernus Pharmaceuticals, Inc. announces the signing of a definitive licensing agreement with United Therapeutics Corporation for the development of UT-15C, United Therapeutics’ oral prostacyclin analog.  The licensing agreement contemplates United Therapeutics’ development of UT-15C for additional indications.

"We are excited about the development of this product and the potential improvement in therapy it brings to patients,” said Jack Khattar, President and CEO of Supernus.  “UT-15C utilizes EnSoTrol®, our advanced osmotic technology that is designed to deliver unique release profiles and to address specific challenges in oral delivery.” 

UT-15C is an oral sustained release formulation of treprostinil, the active ingredient in Remodulin^® that is currently marketed for subcutaneous and intravenous treatment of pulmonary arterial hypertension.  Under the license agreement, Supernus will receive milestone payments and royalties from United Therapeutics based on the sales of UT-15C.  Commercial scale-up activities for UT-15C are ongoing and United Therapeutics has recently started late stage multi-national placebo-controlled clinical studies for the treatment of pulmonary arterial hypertension. 

"Our decision to work with Supernus was based on Supernus’ superior development experience with sustained release formulations and their innovative patented osmotic technology,” said David Mottola, Ph.D., Vice President, Product Development at United Therapeutics. “Our collaboration with Supernus on UT-15C moves us closer to our goal of providing patients the convenience of an oral prostacyclin agent that is administered twice per day.

Supernus Pharmaceuticals, Inc. is a specialty pharmaceuticals company focused on developing products for its own portfolio and in partnership with other pharmaceutical companies, using its proven and patented technologies and product development capabilities. Among its key technologies are ProScreen® and OptiScreen® for lead selection and formulation optimization, Microtrol®, Solutrol® and EnSoTrol®, its oral controlled release technologies, and Avert^SM its reduced abuse potential technology. For more information, visit www.supernus.com.

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products for patients with chronic and life-threatening cardiovascular, cancer and infectious diseases.

# # #

CONTACT

Woody Bryan, VP Business Development